Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT05491057
Treatment Patterns of Neratinib in HER2+ EBC in China
Sponsor: Pierre Fabre Medicament
View on ClinicalTrials.gov
Summary
This is a multicenter, open-label, single-arm, non-interventional study to investigate the treatment patterns of Neratinib in HER2-positive early-stage breast cancer in China
Official title: A Multicenter, Open-label, Single-arm, Non-interventional Study to Investigate the Treatment Patterns of Nerlynx® (Neratinib) in HER2-positive Early-stage Breast Cancer in China
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2022-09-30
Completion Date
2026-06-30
Last Updated
2022-08-08
Healthy Volunteers
No
Conditions
Interventions
DRUG
Neratinib
Neratinib standard dose 240 mg once daily for 1 year
Locations (1)
Medical Affair
Shanghai, China